Answers are grounded in this paper and cite their sources.
Background Anti-phospholipase A2 receptor (anti-PLA2R)-associated membranous nephropathy (MN) is a primary form of autoimmune glomerulonephritis causing nephrotic syndrome. MN can develop a refractory or relapsing clinical course, but biomarkers associated with poor prognosis remain poorly defined. Methods We performed single-nucleus RNA-sequencing (snRNA-seq) and ATAC-sequencing (snATAC-seq) of peripheral immune cells from five refractory/relapsing MN, six remission MN, twelve disease-control and seven healthy individuals (HCs), and GeoMx spatial transcriptomics of diagnostic kidney biopsies from eight refractory/relapsing MN, eight remission MN and eight HCs. Results B cells from refractory/relapsing MN showed significantly reduced CD83 expression. After re-clustering B cells according to CD83 expression, we found that the CD83-high B cells, characterized by upregulation of BACH2, FOXP1, and FOXO1 exhibited significantly lower CD83 expression in the refractory/relapsing MN. Regulatory T cells (Tregs) were also reduced in refractory/relapsing MN. Conversely, glomerular transcriptomes showed minimal differences between refractory/relapsing and remission MN. Conclusions Our findings suggest that CD83-high B cells and Tregs are potential biomarkers and therapeutic targets for refractory/relapsing MN.
No takes yet. Share an insight, caveat, or question.
Kang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: